Anzeige
Mehr »
Freitag, 27.02.2026 - Börsentäglich über 12.000 News
Hochgradiger Fund in Kanada: Steht dieser Rohstoff-Explorer vor der Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Tradegate
26.02.26 | 09:44
5,080 Euro
-1,93 % -0,100
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
4,8354,88516:53
4,8354,88516:53

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMedian Technologies to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis LCS198Webcasts on February 26, 2026, at 5:45 pm CET (held in French): sign-up link and 6:45 pm CET/12:45 pm ET (held in English): sign-up link Regulatory News: Median Technologies (FR0011049824, ALMDT...
► Artikel lesen
18.02.Median Technologies: FDA Clearance Sets Stage for U.S. Commercialization of eyonis LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.402Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway...
► Artikel lesen
12.02.Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis LCS Software as a Medical Device in the United States345The collaboration follows FDA 510(k) clearance for eyonis LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the Tempus...
► Artikel lesen
11.02.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31, 2026301Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
09.02.Median Technologies receives FDA clearance for lung cancer AI tool8
09.02.Median Technologies Receives FDA 510(k) Clearance for eyonis LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening495eyonis LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential...
► Artikel lesen
19.01.Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026322Record iCRO bookings in 2025; order backlog at an all-time high of €76.6 million despite negative forex impact of (6.5) million 2025 revenue of €23.5 million, up 2.6% vs 2024 despite negative...
► Artikel lesen
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
14.01.Median Technologies: H1 2026 Financial Communication Calendar316Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
07.01.Half Year Median Technologies Liquidity Contract Statement587Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following resources were...
► Artikel lesen
05.01.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31, 2025243Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
08.12.25Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis LCS to Patients Across the U.S. and Europe338Non-exclusive commercial agreement for the distribution of eyonis LCS in the United States and Europe The agreement will become effective upon FDA 510(k) clearance Partner's robust...
► Artikel lesen
03.12.25Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30, 2025331Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
25.11.25Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting447Peer-reviewed scientific presentation: "Rethinking Lung Cancer Screening: Longitudinal AI/ML Diagnostics beyond Nodule Size Growth" AI Theater Presentation: "eyonis LCS: Transforming Lung...
► Artikel lesen
13.11.25Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31, 2025325Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
03.11.25Lion Point Capital founder joins Median Technologies board3
03.11.25Median Technologies Appoints Didric Cederholm to Its Board of Directors343Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
28.10.25Median Technologies: €19 Million EIB Financing Raised To Boost AI-Enabled Cancer Diagnosis Platform2
23.10.25Median Technologies Reports First-Half 2025 Financial Results and Provides Key Q3 2025 Business Results469Operating loss reduced by €4 million in first six months of 2025 versus H1 2024, highlighting improved corporate efficiency H1 2025 revenues at €11.3 million, vs €10.9 million in H1 2024...
► Artikel lesen
21.10.25Median Technologies Receives €19 Million From the European Investment Bank, Corresponding to the First Tranche Under the 2025 Loan Facility368Proceeds to support the commercial launch of eyonis®LCS in the U.S. and Europe, and accelerate the broader development of eyonis®, Median's AI-powered Software as a Medical Device suite for early...
► Artikel lesen
13.10.25Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders' Ordinary and Extraordinary General Meeting on October 31, 2025294Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Ordinary and Extraordinary...
► Artikel lesen
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1